Chimeric antigen receptors (CARs) provide a powerful means to augment T cell-based anticancer efficacy, and second-generation CARs have shown remarkable results in clinical trials. Here, the authors discuss the immunopharmacology of the different CAR constructs that are currently in clinical testing.
- Sjoukje J. C. van der Stegen
- Mohamad Hamieh
- Michel Sadelain
